The Expert-Guided Poster Tour is a new innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects.

The Expert-Guided Poster Tour consists of two parts: The first part is reserved for poster viewing. The posters will be on display for 2 hrs before the start of the Guided Poster Tour. During the second part of the Tour, the two experts acting as moderators, will ask questions to poster presenters.

PT104

The assessment of the ERSPC and PCPT2.0 risk calculators in the prediction of prostate cancer in men attending a prostate assessment clinic

By: Kc S., King T., Mak D., London D., Bhatt R., Doherty A., Viney R., Patel P., Kelly B.
University Hospital Birmingham, Dept. of Urology, Birmingham, United Kingdom

PT105

Effects of introducing pre-biopsy mpMRI into contemporary UK prostate cancer detection

By: Hobbs C., Eyre K., Mccormick R., Gleeson F., Macpherson R., Verrill C., Hamdy F., Brewster S., Bryant R.
1Oxford University Hospitals NHS Foundation Trust, Dept. of Urology, Oxford, United Kingdom,
2Oxford University Hospitals NHS Foundation Trust, Dept. of Radiology, Oxford, United Kingdom,
3Oxford University Hospitals NHS Foundation Trust, Dept. of Pathology, Oxford, United Kingdom

PT106

A nurse led clinic for suspected prostate cancer referrals is safe, cost and time efficient

By: Drudge-Coates L., Khati V., Ballesteros R., Martyn-Hemphill C., Brown C., Green J., Challacombe B., Muir G.
1King's College Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom,
2Barts Health NHS Trust, Dept. of Urology, London, United Kingdom,
3Guy's & St Thomas’ NHS Foundation Trust, Dept. of Urology, London, United Kingdom

PT107

Can we eliminate the biopsy for the gland of MRI negative side?

PT108

Is local anaesthetic transperineal prostate biopsy feasible and acceptable: A comparison of patient experience under local anaesthetic or sedation

By: Valero Sarmiento L. 1, Marenco J.L. 2, Moore C. 2, Orczyk C. 2, Collins T. 2, Emberton M. 2
1University College of London, Dept. of Anaesthesia, London, United Kingdom, 2University College of London, Dept. of Uro-Oncology, London, United Kingdom

PT109

Zonal distribution of prostate cancer foci in patients undergoing initial and multiple biopsy series: MRI fusion targeted results from 1,365 patients

By: Leyh-Bannurah S-R. 1, Kachanov M. 1, Beyersdorff D. 2, Preisser F. 1, Fisch M. 3, Graefen M. 1, Budäus L. 1
1Martini-Klinik, Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 2University Medical Center Hamburg-Eppendorf, Department for Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg, Germany, 3University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

PT110

Withdrawn
To be confirmed

PT111

Multiparametric ultrasound: Combining greyscale, shearwave elastography and contrast-enhanced imaging for the localization of significant prostate cancer: Comparison with radical prostatectomy specimens

By: Mannaerts C. 1, Wildeboer R. 2, Postema A. 1, Hagemann J. 3, Massimo M. 2, Wijkstra H. 1, Salomon G. 3
1AMC University Hospital, Dept. of Urology, Amsterdam, Netherlands, The, 2Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven, Netherlands, The, 3University Hospital Hamburg-Eppendorf, Martini Clinic Prostate Cancer Center, Hamburg, Germany

PT112

A multiparametric approach for dynamic contrast-enhanced ultrasound imaging of prostate cancer

By: Wildeboer R. 1, Postema A. 2, Kuenen M. 3, Wijkstra H. 2, Mischi M. 1
1Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven, Netherlands, The, 2Academic Medical Center University of Amsterdam, Dept. of Urology, Amsterdam, Netherlands, The, 3Philips Research, Dept. of In-Body Systems, Eindhoven, Netherlands, The

PT113

Improvement of prostate cancer detection rate using transrectal ultrasound-MRI targeted biopsy: The role of a CAD system combined to multiparametric MRI

By: Pecoraro M. 1, Campa R. 1, Barchetti G. 1, Ceravolo I. 1, Simone G. 2, Leonardo C. 3, Panebianco V. 1
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT114</td>
<td>Innovative diffusion MRI protocol to improve prostate cancer diagnosis</td>
<td>Shenhar C. 1, Degani H. 2, Bar Y. 1, Baniel J. 1, Tamir S. 3, Binyaminov O. 3, Furman-Haran E. 2, Margel D. 1</td>
<td>1 Rabin Medical Center, Dept. of Urology, Petach Tikva, Israel, 2 Weizmann Institute of Science, Dept. of Biological Regulation, Rehovot, Israel, 3 Rabin Medical Center, Dept. of Imaging, Petach Tikva, Israel</td>
</tr>
<tr>
<td>PT115</td>
<td>The learning curve of MRI-US fusion prostate biopsies</td>
<td>Margel D. 1, Ber Y. 1, Sela S. 1, Belo I. 1, Tabachnik T. 1, Benjaminov O. 2, Tamir S. 2, Baniel J. 1</td>
<td>1 Beilinson Hospital, Dept. of Urology, Petach Tikva, Israel, 2 Beilinson Hospital, Dept. of Imaging, Petach Tikva, Israel</td>
</tr>
<tr>
<td>PT117</td>
<td>Characteristics of global Gleason grading for MRI-targeted biopsy in comparison with systematic biopsy and prostatectomy grades</td>
<td>Matsuoka Y. 1, Tanaka H. 2, Kimura T. 2, Waseda Y. 1, Uehara S. 1, Yasuda Y. 1, Kijima T. 1, Yoshida S. 1, Yokoyama M. 1, Ishioka J. 1, Saito K. 1, Kihara K. 1, Fujii Y. 1</td>
<td>1 Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, 2 Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan</td>
</tr>
<tr>
<td>PT119</td>
<td>Active surveillance in a high-volume centre: Oncological outcomes and management changes during a 12 years experience</td>
<td>Catellani M. 1, Luzzago S. 1, Mistretta F.A. 1, Conti A. 1, Russo A. 1, Bianchi R. 1, Di Trapani E. 1, Cozzi G. 1, Petralia G. 2, Ferro M. 1, Musi G. 1, Matei D.V. 1, De Cobelli O. 1</td>
<td>1 IEO European Institute of Oncology, Dept. of Urology, Milan, Italy, 2 IEO European Institute of Oncology, Dept. of Radiology, Milan, Italy</td>
</tr>
</tbody>
</table>
**Baseline characteristics in an MRI-based active surveillance cohort: Association with clinical and histological outcomes**

By: Stavrinides V.¹, Giganti F.¹, Stabile A.¹, Allen C.², Punwani S.², Whitaker H.¹, Emberton M.¹, Moore C.¹

¹University College London, Dept. of Surgery and Interventional Science, London, United Kingdom, ²University College London Hospitals NHS Foundation Trust, Dept. of Radiology, London, United Kingdom

**Cost consequences of alternative MRI-based follow-up strategies in active surveillance of prostate cancer: A decision tree model study based on micro-costing**

By: Elkjaer M.C.¹, Søgaard R.², Andersen M.H.¹, Borre M.¹, Pedersen B.G.³

¹Aarhus University Hospital, Dept. of Urology, Aarhus N, Denmark, ²Aarhus University, Dept. of Public Health, Aarhus, Denmark, ³Aarhus University Hospital, Dept. of Radiology, Aarhus N, Denmark

**Progression and treatment rates using an active surveillance protocol incorporating image guided baseline biopsies and multi-parametric MRI monitoring for men with favourable risk prostate cancer**

By: Thurtle D.¹, Barrett T.², Thankappan-Nair V.¹, Koo B.², Warren A.³, Kastner C.¹, Saeb-Parisy K.¹, Kimberley-Duffell J.⁴, GnanaPragasam V.⁴

¹Cambridge University Hospitals NHS Trust, Dept. of Urology, Cambridge, United Kingdom, ²Cambridge University Hospitals NHS Trust, Dept. of Radiology, Cambridge, United Kingdom, ³Cambridge University Hospitals NHS Trust, Dept. of Pathology, Cambridge, United Kingdom, ⁴University of Cambridge, Academic Urology Group, Cambridge, United Kingdom

**Increasing trend of non-interventional treatment management in patients candidate to active surveillance with localized prostate cancer**

By: Bandini M.¹, Suardi N.¹, Moschini M.¹, Smith A.², Bondarenko H.³, Nazzani S.⁴, Marchioni M.⁵, Preisser F.⁶, Tian Z.³, Abdollah F.⁷, Schips L.⁸, Montorsi F.¹, Shariat S.⁹, Saad F.³, Briganti A.¹, Karakiewicz P.³

¹IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Division of Oncology/Unit of Urology, URI, Milan, Italy, ²University of Montreal Health Center, Division of Urology/Urologic Oncology, Montréal, Canada, ³University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montréal, Canada, ⁴Policlinico San Donato, University of Milan, Academic Dept. of Urology, Milan, Italy, ⁵SS Annunziata Hospital, Dept. of Urology, Chieti, Italy, ⁶University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁷Henry Ford Hospital, Henry Ford Health System, Vattikutti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation (VCore), Detroit, United States of America, ⁸SS Annunziata Hospital, Dept. of Urology, Chieti, Italy, ⁹Medical University of Vienna, Dept. of Urology, Vienna, Austria

**MRI detection of clinically significant prostate cancer in non-index tumors: Implications for focal therapy**
PT125

MRI-guided transurethral ultrasound ablation in patients with localized prostate cancer: 3-year outcomes of a prospective phase I clinical trial


1London Health Sciences Center, Dept. of Urology and Radiology, London, Canada, 2Beaumont Health System, Dept. of Urology, Royal Oak, United States of America, 3German Cancer Research Center (DKFZ), Dept. of Urology and Radiology, Heidelberg, Germany, 4Profound Medical Inc., Dept. of Clinical Affairs, Mississauga, Canada

PT126

Office-based MRI/US fusion target prostate cancer cryoablation under local anaesthesia: 301 patients


Urological Research Network, Dept. of Urology, Miami, United States of America

PT127

Combined clinical parameters and multiparametric MRI for prediction of side-specific extraprostatic disease - a risk-model for patient-tailored risk stratification before radical prostatectomy

By: Radtke J.P. 1, Wiesenfarth M. 2, Hadaschik B. 3, Hithalter B. 1, Kesch C. 4, Schütz V. 1, Alt C. 5, Roth W. 6, Wieczorek K. 7, Duensing S. 1, Roethke M.C. 8, Schlemmer H-P. 8, Hohenfellner M. 1, Bonekamp D. 8, Teber D. 1

1University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 2German Cancer Research Center, Dept. of Biostatistics, Heidelberg, Germany, 3University Hospital Essen, Dept. of Urology, Essen, Germany, 4University of British Columbia, The Vancouver Prostate Centre, Vancouver, Canada, 5Medical Faculty of the Heinrich-Heine-University Dusseldorf, Institute of Diagnostic and Interventional Radiology, Dusseldorf, Germany, 6University Medicine Mainz, Institute of Pathology, Mainz, Germany, 7University of Heidelberg, Institute of Pathology, Heidelberg, Germany, 8German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany

PT128

Staging with Ga-68 HBED-CC-Glu-NH-CO-NH-Lys (Ahx) PSMA-11 PET CT (PSMA) prior to radical prostatectomy has high predictive value in assessing biochemical response to surgery

By: Emmett L. 1, Nandurkar R. 1, Van Leeuwen P. 2, Woo H. 3, Kooner R. 4, Ende D. 4
PT129

**Is fatal family history in prostate cancer a predictor of radical prostatectomy outcomes?**

By: Herkommer K. 1, Strüh J. 1, Kron M. 2, Kranz S. 1, Sander S. 2, Gschwend J.E. 1

1 Klinikum rechts der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany,
2 University of Ulm, Institute for Epidemiology and Biometry, Ulm, Germany

---

PT130

**Early versus standard catheter removal after complete anatomical reconstruction during robot-assisted radical prostatectomy: Results from a prospective single-institutional randomized trial (RIPRECA)**

By: Lista G. 1, Lughezzani G. 1, Buffi N. 1, Peschecura R. 1, Lazzeri M. 1, Casale P. 1, Hurle R. 1, Pasini L. 1, Cardone P. 1, Zandegiacomo S. 1, Benetti A. 1, Saita A. 1, Guazzoni G. 2

1 Istituto Clinico Humanitas, Dept. of Urology, Rozzano, Italy,
2 Istituto Clinico Humanitas, IRCCS, Humanitas University, Dept. of Urology, Rozzano, Italy

---

PT131

**Robotic perineal radical prostatectomy: Initial experience with 30 cases**

By: Tugcu V. 1, Akca O. 2, Simşek A. 1, Ismail Y. 1, Sahin S. 1, Yenice G. 1, Tasci A. 1

1 University of Health Sciences, Istanbul Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Dept. of Urology, Istanbul, Turkey,
2 University of Health Sciences, Istanbul Kartal Dr. Lutfi Kirdar Research and Training Hospital, Dept. of Urology, Istanbul, Turkey

---

PT132

**Functional outcomes and post-operative complications in elderly patients (> 65 years old) undergoing robotic-assisted radical prostatectomy**

By: Harmouch S. 1, Traboulsi S. 1, Tholomier C. 2, Couture F. 3, Bondarenko H. 1, Negrean C. 1, Karakiewicz P. 1, El-Hakim A. 1, Zorn K.C. 1

1 University of Montreal, Dept. of Urology, Montreal, Canada,
2 University of Mcgill, Dept. of Urology, Montreal, Canada,
3 University of McGill, Dept. of Urology, Montreal, Canada

---

PT133

**How do urinary incontinence and PSA recurrence affect health related QoL after radical prostatectomy?**


Wakayama Medical University, Dept. of Urology, Wakayama, Japan